Mutant SnxA protein that binds specifically to phosphatidylinositol phosphate

Modified and artificial proteins that bind to a variety of lipid molecules can be prepared using similar techniques.

A Method for Elongating Peptide Chains Two Residues at a time

A method for synthesizing two-residue elongated peptides using microflow synthesis, taking advantage of both the nucleophilic and electrophilic reactivity of amino acid N-carboxyanhydrides (NCAs).

Synthesis of Peptides Combining α-Disubstituted Amino Acids (Aib) and N-Methyl Amino Acids

A method for synthesizing a peptide composed of bulky Aib and N-methyl amino acids using a microflow synthesis.

Blood-Brain Barrier DDS Peptide

A cyclic peptide for highly efficient delivery into the brain with macromolecular drugs.

Treatment and Biomarker for Hepatocellular Carcinoma caused by Sinusoidal Hypertension

Inhibitor of the integrin αV‒CTGF axis, which is activated in response to increased hepatic sinusoidal pressure.

Catalysts for the Synthesis of Amide Compounds and Peptides

A low-cost, highly reactive catalyst for the dehydrative condensation of carboxylic acids and amines, enabling condensing agent-free and environmentally friendly amide synthesis.

Small molecule conjugated oligonucleotide for enhancing delivery to the spleen

This technology utilizes small-molecule ligands that enhance the efficacy of oligonucleotide therapeutics in reducing gene expression within the spleen.

Bone Formation Promoter for Fractures, Spinal Fixation, Osteoporosis

A complex of bone morphogenetic protein (BMP2, FGF2, etc.) and polysulfated glycopeptide promotes bone formation by specifically delivering, accumulating, and maintaining the concentration of BMP2 on the bone surface.

Fusion Protein Anticancer Drug Targeting RAS

Fusion protein X, which combines a RAS-binding domain, a cell membrane-permeable peptide, and a third domain, inhibits the function of activated RAS and degrades it.

Therapeutics for Fibrosis Targeting RIG-I

A drug candidate for the treatment of various fibrosis, incorporating a ligand for RIG-I, a pattern recognition receptor, as the active ingredient.

Treatment of interstitial cystitis with integrin inhibitors

Novel targets identified from genetic analysis of a model animal and patients that differ from previous therapeutic approaches

RI-labeled antibody drugs that do not accumulate in the kidney

Safe molecular design that allows RI to be rapidly excreted into the urine by providing a tubule-specific enzyme cleavage sequence between the RI chelating site and the antibody

Novel Drug Target for Endometriosis

Identification of prostaglandin receptors involved in the pathogenesis of endometriosis. [Collaborative Research Proposal]

Highly Efficient Intestinal Delivery and Absorption DDS Peptide

Oral DDS technology using cyclic peptides of D-amino acids that can reach the small intestine while suppressing degradation in the digestive tract and allowing highly efficient permeation through the intestinal epithelium.

Keton Body BHB Nanoparticle Prodrug

For acute kidney injury, inflammatory bowel disease, depressions, etc.

Inducer for Systemic Anti-tumor Immunity

A novel therapeutic approach for systemic anti-tumor immunity utilizing apolipoproteins

Orally administered insulin

Oral insulin formulation with peptide DDS technology for high intestinal absorption efficiency.

Novel cancer immunotherapy antibodies targeting soluble CD155

Targeting soluble CD155, an immune escape mechanism of tumor cells, activates cancer immunity through DNAM-1-mediated activation signals on T cells

Anti-Obesity and/or Anti-Diabetes Drug

Therapeutic mechanism based on enhancement of adipocyte activation (promotion of UCP1 expression and mitochondrial activation) by SerpinA1.

Novel NASH Ex vivo Model using Hepatic Organoids Connected to Bile Ducts (HBTO)